Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Myrthe M A Toorop"'
Autor:
Milou A. M. Stals, Marco J. J. H. Grootenboers, Coen vanGuldener, Fleur H. J. Kaptein, Sander J. E. Braken, Qingui Chen, Gordon Chu, Erik M. vanDriel, Antonio Iglesias del Sol, Evert deJonge, K. Merijn Kant, Fleur Pals, Myrthe M. A. Toorop, Suzanne C. Cannegieter, Frederikus A. Klok, Menno V. Huisman, the Dutch COVID & Thrombosis Coalition (DCTC)
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 5, Iss 3, Pp 412-420 (2021)
Abstract Background Whereas accumulating studies on patients with coronavirus disease 2019 (COVID‐19) report high incidences of thrombotic complications, large studies on clinically relevant thrombosis in patients with other respiratory tract infec
Externí odkaz:
https://doaj.org/article/cd66aa34f5e5426e93e37e45c14001b7
Autor:
LUMC-COVID-19 Research Group, Qingui Chen, Myrthe M. A. Toorop, Mark G. J. de Boer, Frits R. Rosendaal, Willem M. Lijfering
Publikováno v:
BMC Public Health, Vol 20, Iss 1, Pp 1-10 (2020)
Abstract Background To evaluate the association between crowding and transmission of viral respiratory infectious diseases, we investigated the change in transmission patterns of influenza and COVID-19 before and after a mass gathering event (i.e., c
Externí odkaz:
https://doaj.org/article/fea1cef8024d479abbed632322ffacf7
Autor:
Myrthe M. A. Toorop, Nienke vanRein, Melchior C. Nierman, Helga W. Vermaas, Menno V. Huisman, Felix J. M. van derMeer, Suzanne C. Cannegieter, Willem M. Lijfering
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 4, Iss 4, Pp 586-593 (2020)
Abstract Background Many patients who used vitamin K antagonists (VKAs) for long‐term prevention of thromboembolism are now actively switched to a direct oral anticoagulant (DOAC). Strict adherence to a DOAC is crucial for its success. However, the
Externí odkaz:
https://doaj.org/article/d66244669c374611bb64e83c57f133f9
Autor:
Felix J. M. van der Meer, Melchior C Nierman, Laura M. Faber, Marieke J. H. A. Kruip, Myrthe M A Toorop, Suzanne C. Cannegieter, Qingui Chen, Lies Goede, Willem M. Lijfering
Publikováno v:
Journal of Thrombosis and Haemostasis. WILEY
Journal of Thrombosis and Haemostasis
Journal of Thrombosis and Haemostasis, 20(2), 339-352. WILEY
Journal of Thrombosis and Haemostasis, 20(2), 339-352. Wiley-Blackwell Publishing Ltd
Journal of Thrombosis and Haemostasis
Journal of Thrombosis and Haemostasis, 20(2), 339-352. WILEY
Journal of Thrombosis and Haemostasis, 20(2), 339-352. Wiley-Blackwell Publishing Ltd
Background: Non-valvular atrial fibrillation (NVAF) patients are advised to switch from a vitamin K antagonist (VKA) to direct oral anticoagulant (DOAC) when time in therapeutic range (TTR) is low. Objective: To examine if pre-switch TTR determines p
Autor:
Suzanne C. Cannegieter, Qingui Chen, Willem M. Lijfering, Vladimir Tichelaar, Myrthe M A Toorop
Publikováno v:
European Heart Journal, 42(40), 4126-+. OXFORD UNIV PRESS
European Heart Journal, 42(40), 4126-4137. OXFORD UNIV PRESS
European Heart Journal, 42(40), 4126-4137. Oxford University Press
European Heart Journal
European Heart Journal, 42(40), 4126-4137. OXFORD UNIV PRESS
European Heart Journal, 42(40), 4126-4137. Oxford University Press
European Heart Journal
Aims Persistence with direct oral anticoagulants (DOACs) has become a concern in non-valvular atrial fibrillation (NVAF) patients, but whether this affects prognosis is rarely studied. We investigated the persistence with oral anticoagulants (OACs) a
Autor:
Qingui Chen, Myrthe M. A. Toorop, Laurens F. Tops, Willem M. Lijfering, Suzanne C. Cannegieter
Publikováno v:
JAMA Network Open. 6:e239973
ImportanceThe temporal trend in adverse events regarding stroke prevention for nonvalvular atrial fibrillation (NVAF) in the direct oral anticoagulant (DOAC) era was rarely investigated comprehensively, especially taking into account potential change
Autor:
Menno V. Huisman, Helga W. Vermaas, Willem M. Lijfering, Felix J. M. van der Meer, Nienke van Rein, Suzanne C. Cannegieter, Melchior C Nierman, Myrthe M A Toorop
Publikováno v:
Research and practice in thrombosis and haemostasis, 4(4), 586-593. Wiley-Blackwell Publishing Ltd
Research and Practice in Thrombosis and Haemostasis, 4(4), 586-593. WILEY
Research and Practice in Thrombosis and Haemostasis, Vol 4, Iss 4, Pp 586-593 (2020)
Research and Practice in Thrombosis and Haemostasis
Research and Practice in Thrombosis and Haemostasis, 4(4), 586-593. WILEY
Research and Practice in Thrombosis and Haemostasis, Vol 4, Iss 4, Pp 586-593 (2020)
Research and Practice in Thrombosis and Haemostasis
Background Many patients who used vitamin K antagonists (VKAs) for long‐term prevention of thromboembolism are now actively switched to a direct oral anticoagulant (DOAC). Strict adherence to a DOAC is crucial for its success. However, therapy adhe
Autor:
Suzanne C. Cannegieter, Frederikus A. Klok, K Merijn Kant, Sander J.E. Braken, Qingui Chen, M A M Stals, Fleur Pals, Myrthe M A Toorop, F H J Kaptein, Menno V. Huisman, Marco J. J. H. Grootenboers, Gordon Chu, Coen van Guldener, Evert de Jonge, Antonio del Sol, Erik M van Driel, Dutch Covid Thrombosis Coalition
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, 5(3), 412-420. WILEY
Research and Practice in Thrombosis and Haemostasis
Research and Practice in Thrombosis and Haemostasis, Vol 5, Iss 3, Pp 412-420 (2021)
Research and Practice in Thrombosis and Haemostasis
Research and Practice in Thrombosis and Haemostasis, Vol 5, Iss 3, Pp 412-420 (2021)
BackgroundWhereas accumulating studies on COVID-19 patients report high incidences of thrombotic complications, large studies on clinically relevant thrombosis in patients with other respiratory tract infections are lacking. How this high risk in COV
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36675575ec101673f777f7d1e2e25bca
http://hdl.handle.net/1887/3230131
http://hdl.handle.net/1887/3230131
Publikováno v:
Journal of Thrombosis and Haemostasis, 18(12), 3163-3168. WILEY
Journal of Thrombosis and Haemostasis
Journal of Thrombosis and Haemostasis
Direct oral anticoagulants (DOACs) are increasingly used for treatment and prevention of thromboembolic diseases, used in fixed dose regimens. Although their safety and efficacy profiles are considered optimal, clinical events still occur. Given that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65a2fdf77b7dd9477b6b3da2e69d6ca1
https://hdl.handle.net/1887/3184744
https://hdl.handle.net/1887/3184744
Autor:
Myrthe M A Toorop, Nienke van Rein, Felix J. M. van der Meer, Willem M. Lijfering, Suzanne C. Cannegieter, Mettine H.A. Bos, Pieter H. Reitsma
Publikováno v:
Thrombosis and Haemostasis, 121(01), 70-75. GEORG THIEME VERLAG KG
Background Major bleeding occurs in 1 to 3% of patients treated with oral anticoagulants per year. Biomarkers may help to identify high-risk patients. A proposed marker for major bleeding while using anticoagulants is soluble thrombomodulin (sTM). Me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8049febeb33e8619d666c8f712229ffe
http://hdl.handle.net/1887/3230124
http://hdl.handle.net/1887/3230124